ID   PEA1
AC   CVCL_2682
DR   cancercelllines; CVCL_2682
DR   CancerTools; 151678
DR   Cell_Model_Passport; SIDM01426
DR   Cosmic; 1305317
DR   DepMap; ACH-001628
DR   ECACC; 10032306
DR   GEO; GSM459742
DR   GEO; GSM459851
DR   GEO; GSM2474996
DR   GEO; GSM4973219
DR   GEO; GSM4973225
DR   GEO; GSM4973231
DR   GEO; GSM4973237
DR   GEO; GSM4973249
DR   GEO; GSM4973261
DR   GEO; GSM4973243
DR   GEO; GSM4973255
DR   GEO; GSM4973267
DR   PRIDE; PXD020764
DR   Progenetix; CVCL_2682
DR   Wikidata; Q54946892
DR   Ximbio; 151678
RX   PubMed=3167863;
RX   PubMed=20581869;
RX   PubMed=22183581;
RX   PubMed=23415752;
RX   PubMed=25230021;
RX   PubMed=28273451;
RX   PubMed=35028612;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Doubling time: 37 hours (PubMed=3167863).
CC   Sequence variation: Mutation; HGNC; 952; BARD1; Simple; p.Trp218Ter (c.653G>A); ClinVar=VCV000482781; Zygosity=Unspecified (PubMed=25230021).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Unspecified (PubMed=25230021; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DepMap; ECACC; PubMed=22183581; PubMed=25230021
ST   Amelogenin: X
ST   CSF1PO: 14
ST   D13S317: 8
ST   D16S539: 12,13
ST   D18S51: 14,17 (DepMap; PubMed=25230021)
ST   D18S51: 11,14,17 (PubMed=22183581)
ST   D19S433: 12,13
ST   D21S11: 30
ST   D2S1338: 19,25
ST   D3S1358: 16,17
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 14
ST   FGA: 22,25
ST   Penta D: 13,15
ST   Penta E: 7,12,13 (DepMap)
ST   Penta E: 7,13 (PubMed=25230021)
ST   TH01: 9
ST   TPOX: 8,12
ST   vWA: 18
DI   NCIt; C5228; Ovarian cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2683 ! PEA2
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=3167863;
RA   Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A.,
RA   Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.;
RT   "Characterization and properties of nine human ovarian adenocarcinoma
RT   cell lines.";
RL   Cancer Res. 48:6166-6172(1988).
//
RX   PubMed=20581869; DOI=10.1038/onc.2010.245;
RA   Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J.,
RA   Langdon S.P., Huntsman D.G., Brenton J.D.;
RT   "Genomic analysis of genetic heterogeneity and evolution in high-grade
RT   serous ovarian carcinoma.";
RL   Oncogene 29:4905-4913(2010).
//
RX   PubMed=22183581; DOI=10.1002/path.3980;
RA   Ng C.K.Y., Cooke S.L., Howe K.L., Newman S., Xian J., Temple J.,
RA   Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.;
RT   "The role of tandem duplicator phenotype in tumour evolution in
RT   high-grade serous ovarian cancer.";
RL   J. Pathol. 226:703-712(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=35028612; DOI=10.1016/j.xcrm.2021.100471;
RA   Huang D.-Q., Chowdhury S., Wang H., Savage S.R., Ivey R.G., Kennedy J.J.,
RA   Whiteaker J.R., Lin C.-W., Hou X.-N., Oberg A.L., Larson M.C., Eskandari N.,
RA   Delisi D.A., Gentile S., Huntoon C.J., Voytovich U.J., Shire Z.J.,
RA   Yu Q., Gygi S.P., Hoofnagle A.N., Herbert Z.T., Lorentzen T.D.,
RA   Calinawan A., Karnitz L.M., Weroha S.J., Kaufmann S.H., Zhang B.,
RA   Wang P., Birrer M.J., Paulovich A.G.;
RT   "Multiomic analysis identifies CPT1A as a potential therapeutic target
RT   in platinum-refractory, high-grade serous ovarian cancer.";
RL   Cell Rep. Med. 2:100471.1-100471.32(2021).
//